SCHEMBL9448906

SCHEMBL9448906

[N-]=[N+]=CC(=O)c1ccc(Cl)c(Cl)c1

nearest known ligand 0.56

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.52
ALDH1A1 P00352 2/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
HTT P42858 2/20 0.51
HIF1A Q16665 1/20 0.51
SRD5A2 P31213 1/20 0.46
ALOX5 P09917 1/20 0.45
NPC1 O15118 2/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 2/20 0.43
KDM4E B2RXH2 1/20 0.43
PKM P14618 1/20 0.43
HPGD P15428 2/20 0.42
POLB P06746 2/20 0.41
CXCL12 P48061 1/20 0.40
KMO O15229 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9448915 0.84 ALDH1A1 (0.51) TSHRALDH1A1MEN1KMT2AHTT
SCHEMBL30345150 0.84 ALDH1A1 (0.47) TSHRALDH1A1MEN1KMT2AHTT
SCHEMBL9449158 0.84 ALDH1A1 (0.51) ALDH1A1MEN1KMT2AHTTHIF1A
SCHEMBL3932495 0.84 ALDH1A1 (0.47) TSHRALDH1A1MEN1KMT2AHTT
SCHEMBL3867227 0.83 TSHR (0.49) TSHRALDH1A1MEN1KMT2AHTT
SCHEMBL20496758 0.80 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AHTTHIF1A
SCHEMBL9448974 0.80 ALDH1A1 (0.47) ALDH1A1MEN1KMT2AHTTHIF1A
SCHEMBL9448828 0.80 ALDH1A1 (0.47) TSHRALDH1A1MEN1KMT2AHTT
SCHEMBL11597017 0.79 CA1 (0.51) ALDH1A1MEN1KMT2AHTTHIF1A
SCHEMBL2073722 0.79 ALDH1A1 (0.61) TSHRALDH1A1MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10093609-B2 TAK1 kinase inhibitors, compositions, and uses related thereto EMORY UNIVERSITY (US) 2018-10-09 US disclosed
US-20170369417-A1 TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2017-12-28 US disclosed
US-9751825-B2 TAK1 kinase inhibitors, compositions, and used related thereto EMORY UNIVERSITY (US) 2017-09-05 US disclosed
US-20140249199-A1 TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO HEALTH RESEARCH, INC. (US) 2014-09-04 US disclosed
WO-2013012998-A1 TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO EMORY UNIVERSITY (US) 2013-01-24 WO disclosed
EP-0466730-B1 GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS THE UPJOHN COMPANY (US) 1993-07-21 EP disclosed
US-5220021-A Geminal bisphosphonic acids and derivatives as anti-arthritic agents THE UPJOHN COMPANY (US) 1993-06-15 US disclosed
EP-0466730-A1 GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS. UPJOHN CO (US) 1992-01-22 EP disclosed
WO-1990012017-A1 GEMINAL BISPHOSPHONIC ACIDS AND DERIVATIVES AS ANTI-ARTHRITIC AGENTS THE UPJOHN COMPANY (US) 1990-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10093609-B2 TAK1 kinase inhibitors, compositions, and uses related thereto TAB1, MAP3K1, MAP3K6 TSHR 4115/4885ALDH1A1 3504/4885MEN1 1537/4885
US-20140249199-A1 TAK1 KINASE INHIBITORS, COMPOSITIONS, AND USED RELATED THERETO TAB1, MAP3K1, MAP3K6 TSHR 4112/4885ALDH1A1 3574/4885MEN1 1525/4885
US-20170369417-A1 TAK1 Kinase Inhibitors, Compositions, and Uses Related Thereto TAB1, MAP3K1, MAP3K6 TSHR 4115/4885ALDH1A1 3504/4885MEN1 1537/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.